Last reviewed · How we verify

NCT04586894: AMICI

Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors

Completed Last updated 8 June 2023
What this trial tests

trial testing Cardiac MRI in Cancer in 50 participants. Completed in 1 July 2022.

Timeline
6 November 2020
Primary endpoint
1 February 2022
1 July 2022

Quick facts

Lead sponsorAssistance Publique - Hôpitaux de Paris
StatusCompleted
Study typeOBSERVATIONAL
Enrollment50
Start date6 November 2020
Primary completion1 February 2022
Estimated completion1 July 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Cancer or Immune Defect. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our knowledge on cardiovascular side effects of immune checkpoint inhibitors (ICIs) is restricted to this date to observational retrospective data (mainly case series and pharamcovigilance analysis). We aim at assessing the incidence of cardiovascular adverse side effects of ICIs by means of a prospective interventional single centre study using multiple biomarkers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cardiac MRI

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04586894.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing